化疗

 

摘要号：GS2-02

 

Efficacy and utilization trends of adjuvant chemotherapy for stage I， II， and III breast cancer in the elderly population: A National Cancer Database (NCDB) analysis

 

老年人群Ⅰ至Ⅲ期乳腺癌辅助化疗的疗效和应用趋势：国家癌症数据库（NCDB）

 

摘要号：GS2-03

 

Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality， stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27，000 patients

 

新辅助化疗后pCR及对乳腺癌复发和死亡的影响，按乳腺癌亚型和辅助化疗分层：一项27，000余人的个体患者水平荟萃分析

 

摘要号：GS2-04

 

Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

 

CIBOMA / 2004-01_GEICAM / 2003-11研究：一项随机Ⅲ期临床试验评估早期TNBC标准化疗后辅助卡培他滨治疗效果

 

内分泌治疗

 

摘要号：GS3-01

 

A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ

 

一项随机Ⅲ期研究：低剂量TAM用于预防激素敏感性乳腺导管或小叶原位癌复发

 

摘要号：GS3-02

 

PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib

 

PALLET：一项比较letrozole单药或联合palbociclib新辅助治疗的临床效果和抗增殖作用的研究

 

摘要号：GS3-03

 

Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24，912 women

 

延长AI辅助治疗超过5年对复发和病因特异性死亡率的影响：EBCTCG一项纳入12项随机试验、24912名妇女个体患者数据的荟萃分析

 

摘要号：GS3-04

 

A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)

 

将芳香化酶抑制剂辅助治疗延长至10年的前瞻性随机多中心开放标签Ⅲ期试验——来自1697名绝经后妇女的N-SAS BC 05试验结果：Arimidex延长辅助随机研究（AERAS）

 

摘要号：GS4-07

 

Race， ethnicity and clinical outcomes in hormone receptor-positive， HER2-negative， node-negative breast cancer: results from the TAILORx trial

 

HR阳性、HER2阴性、淋巴结阴性乳腺癌的人种、种族和临床结果：TAILORx试验结果

 

摘要号：GS6-03

 

Symptoms and health-related quality of life on endocrine therapy alone (E) versus chemoendocrine therapy (C+E): TAILORx patient-reported outcomes results

 

内分泌治疗和与内分泌联合化疗的症状及健康相关生存质量的对比：TAILORx试验的患者报告

 

乳腺癌风险预测

 

摘要号：GS3-06

 

Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study

 

乳腺癌复发动力学揭示晚期复发ER阳性亚群：来自代谢研究的结果

 

摘要号：GS3-07

 

Clinical utility of circulating tumor cell count as a tool to chose between first line hormone therapy and chemotherapy for ER+HER2-metastatic breast cancer: Results of the phase III STIC CTC trial

 

循环肿瘤细胞计数作为ER+/HER2-转移性乳腺癌一线激素治疗和化疗选择的工具：Ⅲ期STIC CTC试验结果

 

摘要号：GS2-01

 

Age-related breast cancer risk estimates for the general population based on sequencing of cancer predisposition genes in 19，228 breast cancer patients and 20，211 matched unaffected controls from US based cohorts in the CARRIERS study

 

CARRIERS研究：基于来自美国队列的19，228名乳腺癌患者和20，211名未受影响的对照者中，一般人群的癌症易感基因测序的年龄相关乳腺癌风险估计值

 

靶向治疗

 

摘要号：GS3-08

 

Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial

 

Alpelisib +氟维司群用于晚期乳腺癌: 来自Ⅲ期SOLAR-1试验的亚组分析

 

摘要号：GS2-07

 

PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

 

PHARE随机试验最终结果：对比早期乳腺癌6和12个月曲妥珠单抗治疗效果

 

摘要号：P6-17-17

 

Pertuzumab， trastuzumab， and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY)

 

帕妥珠单抗+曲妥珠单抗联合多西他赛新辅助治疗早期或局部晚期HER-2+亚洲乳腺癌患者的疗效和安全性分析的随机对照3期临床研究（PEONY）

 

摘要号：GS1-10

 

Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

 

KATHERINE研究：新辅助治疗后仍有残存病灶早期HER2+乳腺癌患者，T-DM1对比曲妥珠单抗辅助治疗的Ⅲ期研究结果

 

免疫治疗

 

摘要号：GS1-04

 

IMpassion130: Efficacy in immune biomarker subgroups from the global， randomized， double-blind， placebo-controlled， phase III study of atezolizumab + nab-paclitaxel in patients with treatment-na?ve， locally advanced or metastatic triple-negative breast cancer

 

IMpassion130：来自治疗初治、局部晚期或转移性三阴性乳腺癌患者的atezolizumab +白蛋白紫杉醇的全球、随机、双盲、安慰剂对照、Ⅲ期研究的免疫生物标志物亚组的功效

 

摘要号：PD3-01

 

Results from KATE2， a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)

 

KATE2研究结果：atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1在晚期HER2+乳腺癌的随机2期临床研究

 

外科

 

摘要号：GS6-01

 

Surgical treatment after neoadjuvant systemic therapy in young women with breast cancer: Results from a prospective cohort study

 

一项年轻女性乳腺癌新辅助全身治疗后手术治疗的前瞻性队列研究结果

 

摘要号：GS-05

 

The impact of breast cancer surgery on quality of life: Long term results from E5103

 

乳腺癌手术对生活质量的影响：E5103的长期结果

 

摘要号：GS6-06

 

Local therapy and quality of life outcomes in young women with breast cancer

 

乳腺癌年轻女性的局部治疗和生活质量结果

 

12月4日-8日，《肿瘤瞭望》与您共赴乳腺癌“阿拉莫之战”——2018年圣安东尼奥乳腺癌研讨会